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BACKGROUND AND PURPOSE
Phagocyte function is critical for host defense against infections. Defects in phagocytic function lead to several primary
immunodeficiencies characterized by early onset of recurrent and severe infections. In this work, we further investigated the
effects of BAY 41-2272, a soluble guanylate cyclase (sGC) agonist, on the activation of human peripheral blood monocytes
(PBM) and THP-1 cells.
EXPERIMENTAL APPROACH
THP-1 cells and PBM viability was evaluated by methylthiazoletetrazolium assay; reactive oxygen species production by
lucigenin chemiluminescence; gene and protein expression of NAPDH oxidase components by qRT-PCR and Western blot
analysis, respectively; phagocytosis and microbicidal activity by co-incubation, respectively, with zymosan and Escherichia coli;
and cytokine release by ELISA.
KEY RESULTS
BAY 41-2272, compared with the untreated group, increased spreading of monocytes by at least 35%, superoxide production
by at least 50%, and gp91PHOX and p67PHOX gene expression 20 to 40 times, in both PBM and THP-1 cells. BAY 41-2272 also
augmented phagocytosis of zymosan particles threefold compared with control, doubled microbicidal activity against E. coli
and enhanced the release of TNF-a and IL-12p70 by both PBM and THP-1 cells. Finally, by inhibiting sGC with ODQ, we
showed that BAY 41-2272-induced superoxide production and phagocytosis is not dependent exclusively on sGC activation.
CONCLUSIONS AND IMPLICATIONS
In addition to its ability to induce vasorelaxation and its potential application for therapy of vascular diseases, BAY 41-2272
was shown to activate human mononuclear phagocytes. Hence, it is a novel pro-inflammatory drug that may be useful for
controlling infections in the immunocompromised host.
Abbreviations
BAY 41-2272, 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine; BHI, brain heart
infusion broth; CFU, colony-forming unit; CGD, chronic granulomatous disease; DMSO, dimethyl sulfoxide; EPEC,
enteropathogenic Escherichia coli; FHS, fresh human serum; IL-12p70, IL-12 subunit p70; MTT, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide; ODQ, 1H-(1,2,4) oxadiazole (4,3-alpha) quinoxaline-1-one; PBM, peripheral
blood monocytes; PBMC, peripheral blood monocyte cell; PMA, phorbol myristate acetate; ROS, reactive oxygen species;
sGC, soluble guanylyl cyclase
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Introduction
Phagocytes are responsible for the initiation of the immune
response and their primary functions are the identification,
ingestion (phagocytosis) and elimination of microorganisms,
cellular debris and circulating immune complexes (Flannagan
et al., 2009). Phagocytes are very important not only as effec-
tor cells but also as regulators of inflammatory responses, by
releasing cytokines and several other mediators (Aggelidou
et al., 2002). Primary defects in phagocytes result in the early
onset of recurrent infections that lead to death if not properly
managed (Samarghitean et al., 2009).
Chronic granulomatous disease (CGD) is an example of
defective phagocytes, where these cells are unable to produce
reactive oxygen species (ROS), resulting in flawed microbial
killing (Geha et al., 2007). ROS are involved in phagocyte
microbicidal mechanisms and are produced by the NADPH
oxidase system, which consists of four main components,
namely p47PHOX and p67PHOX, found in the cytosol; and
p22PHOX and gp91PHOX, the so-called membrane cytochrome
b558. These components are encoded, respectively, by NCF1,
NCF2, CYBA and CYBB genes (El-Benna et al., 2005). IFN-g
therapy reduces the relative risk of severe infections in 70% in
patients with CGD (Ezekowitz et al., 1988; Kobayashi et al.,
2008); however, the mechanism involved in this reduction,
initially attributed to positive regulation of iNOS (inducible
NOS), has not been confirmed (Condino-Neto et al., 1996).
Therefore, other mechanisms have been investigated to
explain the beneficial effects of IFN-g in CGD (Condino-Neto
and Newburger, 2000).
One of the most biologically relevant actions of NO is its
binding to the haeme moiety in the soluble guanylyl cyclase
(sGC), leading to intracellular accumulation of the second
messenger molecule, cGMP, which, in turn, regulates numer-
ous pathophysiological processes (Pacher et al., 2007). There
is extensive literature showing the relevance of NO in the
microbicidal mechanisms against several intracellular patho-
gens in experimental models (Bogdan, 2001). In addition,
cGMP has been shown to be a key messenger in many cellular
immune processes, such as differentiation, chemotaxis, pro-
liferation and release of soluble mediators (Kobialka and
Gorczyca, 2001; Ciuman et al., 2006).
NO-independent sGC activators have emerged as valuable
tools for investigating the physiopathology of the NO–sGC–
cGMP signalling pathway (Stasch et al., 2001). One of most
studied NO-independent sGC stimulator is BAY 41-2272,
which is reported to act in synergism with NO to produce
anti-aggregating, anti-proliferative and vasodilator effects
(Evgenov et al., 2007). Our group has recently demonstrated
that BAY 41-2272 increases the production of cGMP, release
of superoxide and CYBB gene expression in human THP-1
mononuclear cells (Oliveira-Junior et al., 2007). These find-
ings raise a new perspective for the development of new
therapies for phagocyte defects and to treat infections by
directly activating phagocytes and other cells of the immune
system.
The aim of this work was to further evaluate the effects of
BAY 41-2272 on the activation of human peripheral blood
monocytes (PBM) and THP-1 cells. We specifically investi-
gated the production of superoxide, expression of genes
encoding components of the NADPH oxidase system, spread-
ing, phagocytosis, microbicidal activity and cytokine release
by these cells, all important indicators of phagocyte function.
Methods
Isolation and culture of human PBM and
THP-1 cells
Peripheral blood monocyte cells (PBMC) were obtained from
healthy volunteers and were isolated by density-gradient cen-
trifugation over Ficoll-Paque® (Sigma Chemical Co., St.
Louis, MO, USA), followed by anti-CD16 antibody-labelled
magnetic beads columns for PBM isolation (MACS Separator,
Mylteni Biotec, Bergish Gladbach, Germany). The cells were
washed three times with PBS and re-suspended in RPMI 1640
culture medium supplemented with 10% heat-inactivated
fetal calf serum (Gibco, Grand Island, NY, USA). THP-1 cells
obtained from ATCC (Manassas, VA, USA) (human acute
monocytic leukaemia cell line) were maintained as previously
described (Tsuchiya et al., 1980).
Cell viability
Cell viability was assessed using a method based on the mito-
chondrial reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT; 5 mg·mL-1) to formazan
(Thomazzi et al., 2005). Cells (1 ¥ 106 cells·mL-1, 100 mL) were
treated with either BAY 41-2272 (1.0, 3.0 and 10.0 mM),
phorbol myristate acetate (PMA; 30 and 300 nM) or dimethyl
sulfoxide (DMSO, drug vehicle, 0.7%) for either 30 or
120 min at 37°C. Preliminary screening experiments were
carried out to select effective drug concentrations not toxic to
cells. Previous studies have demonstrated that concentrations
of BAY 41-2272 (up to 10.0 mM) are effective in inducing the
production of cGMP and cAMP in mononuclear cells
(Oliveira-Junior et al., 2007).
Measurement of superoxide production
Superoxide anion production by PBM and THP-1 cells was
measured as described previously (Hatanaka et al., 2006).
After a 48 h incubation with or without BAY 41-2272 (1.0 and
3.0 mM) or IFN-g (100 U·mL-1), a lucigenin (1 mM)-preloaded
cell suspension (1 ¥ 106 cells·mL-1, 100 mL) was stimulated by
adding PMA (30 nM) or IFN-g (100 U·mL-1). The chemilumi-
nescence was monitored for 2 h using a microplate luminom-
eter reader (EG&G Berthold LB96V, Bad Wildbad, Germany),
and the results are expressed as relative light units (RLU).
Peak levels of RLU were recorded to calculate the mean of the
maximum superoxide production during the observation
period.
CYBB, CYBA, NCF1 and NCF2
mRNA expression
mRNA was obtained after lysis of PBM and THP-1 cells
(1 ¥ 107 cells·mL-1) previously treated for 48 h with IFN-g
(100 U·mL-1) or BAY 41-2272 (1.0 and 3.0 mM) using Trizol
reagent (Invitrogen, Carlsbad, CA, USA) followed by reverse
transcription with Super Script III RT and random hexamers
(Invitrogen) to cDNA. For quantitative real-time PCR analy-
sis, SYBR green MasterMix (Applied Biosystems, Foster City,
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CA, USA) was used in an ABI 5700 thermocycler. All results
were normalized to human b-actin. Table 1 shows primers
sequence used in the reactions.
p22PHOX, p47PHOX and p67PHOX protein
expression by Western blot
PBM were first treated with IFN-g (100 U·mL-1) or BAY 41-2272
(1.0 and 3.0 mM) for 48 h. After removal of the medium, cells
(1 ¥ 107 cells·mL-1) were washed in PBS and lysed in ice-cold
lysis buffer [2% Triton X-100, 10 mM Tris–HCl (pH 8),
150 mM NaCl, 2 mM NaN3, 2 mM EDTA] containing protease
inhibitors (Roche Molecular Biochemicals, Indianapolis, IN,
USA) for 45 min at 4°C. The soluble proteins (20 mg) were
separated by 7.5% SDS-PAGE, and the gel was electroblotted
on nitrocellulose membrane (Hybond-ECL; Amersham, Buck-
inghamshire, UK) and then probed with monoclonal antibod-
ies for p22PHOX, p47PHOX, p67PHOX or b-actin, according to the
method described by Chen et al. (2004). The immunoblots
were labelled with horseradish-labelled anti-mouse IgG and
detected via enhancement with chemiluminescence reagent.
The total pixel intensity analyses of the blots were conducted
by using ImageJ 1.44 (developed by Wayne Rasband, National
Institutes of Health, Bethesda, MD, USA; available at http://
rsb.info.nih.gov/ij/index.html).
gp91PHOX protein expression by flow cytometry
Gp91PHOX expression in PBM (1 ¥ 106 cells·mL-1) treated with
PMA (30 nM), IFN-g (100 U·mL-1) or BAY 41-2272 (1.0 and
3.0 mM) for 48 h was assessed by using mAbs directed against
an external epitope of gp91phox (7D5; Yamauchi et al., 2001).
Fluorescence was measured on a FACSCanto II flow cytometry
(BD Biosciences, San Diego, CA, USA), and results are
expressed as percentage of cells expressing gp91PHOX and mean
fluorescence intensity (MFI) values in arbitrary units (au).
Spreading assay
After a 1 or 48 h incubation with BAY 41-2272 (1.0 and
3.0 mM), IFN-g (100 U·mL-1) or PMA (30 nM), PBM and THP-1
cells were labelled with a fluorescent dye, calcein-AM (Blease
et al., 1999). For spreading assays, 100 mL of 1 ¥ 106 cells·mL-1
labelled cells were placed over microscope glass slides for 1 h.
Analysis was performed using a phase-contrast microscope
(Nikon, Tokyo, Japan) at 400¥ magnification. The results are
expressed as the percentage of adherent cells from a total of
200 cells.
Phagocytosis assay
After a 48 h treatment with or without BAY 41-2272 (1.0 and
3.0 mM) or IFN-g (100 U·mL-1), PBM and THP-1 cells (1 ¥ 106
cells·mL-1) were incubated with zymosan (Sigma; 1 ¥ 107
particles·mL-1) for 2 h and stimulated by adding PMA
(30 nM) or IFN-g (100 U·mL-1). Phagocyting cells were
defined on phase-contrast microscope (Nikon) as cells that
internalized two or more particles. Results are expressed as a
percentage of phagocyting cells from a total of 200 cells.
Microbicidal activity
An enteropathogenic Escherichia coli (EPEC) strain was used
for microbicidal assays. EPEC were cultured overnight in
brain heart infusion broth (BHI – Fluka, Bucks, Switzerland)
under shaking, at 37°C, and its concentrations were esti-
mated photometrically (an optical density of 1.0 at 600 nm
was equivalent to 1 ¥ 108 bacteria·mL-1). The CFU assay was
performed as described previously (Bellinati-Pires et al.,
1995). A proportion of 1:10 of cells and EPEC, opsonized or
not with fresh human serum (FHS), were mixed and incu-
bated at 37°C under shaking for 30, 60, 90 and 120 min, after
which cells were lysed with 1.5% Triton X-100. Recovered
bacteria were re-suspended in BHI broth and plated on BHI
agar for an overnight incubation at 37°C. The colonies were
counted and the CFU number was converted to % bacteria
survived (Bellinati-Pires et al., 1995). Microbicidal activity
was calculated as follows: 100 – [(CFU at time t/CFU at time
0) ¥ 100] and expressed as % of maximum microbicidal activ-
ity (minimum % bacteria survived).
Cytokine production
PBM and THP-1 cells were cultured at 1 ¥ 106 cells·mL-1 into
12-well plates treated with BAY 41-2272 (1.0 and 3.0 mM) or
IFN-g (100 U·mL-1) for 48 h. Supernatants were collected and
assayed by ELISA for IL-12p70 or TNF-a release (BD Bio-
sciences) as described previously (Pitzurra et al., 2000).
BAY 41-2272 actions through sGC pathway
We performed a number of experiments using ODQ [100 mM
1H-(1,2,4) oxadiazole (4,3-a) quinoxaline-1-one], a specific
sGC inhibitor, to investigate the effects of BAY 41-2272 on
superoxide production and phagocytosis mediated through
the sGC pathway. We established two groups of treatments:
(i) cells treated for 2 h together or not with PMA (30 nM),
IFN-g (100 U·mL-1) or BAY 41-2272 (1.0 and 3.0 mM); (ii) cells
Table 1
Real-time PCR primers sequences of genes encoding components of NADPH system
Protein/gene Forward primer Reverse primer
p22phox (CYBA) 5′-atg tgg gcc aac gaa cag-3′ 5′-gta ctc cag cag gca cac aa-3′
gp91phox (CYBB) 5′-ttg tgg aaa ccc tcc tat ga-3′ 5′-aaa acc gca cca acc tct c.-3′
p47phox (NCF1) 5′-cct ctt tcc agt gca ttt aag g-3′ 5′-gat gtg acg gat gaa ggt gtc-3′
p67phox (NCF2) 5′-cgg aca aga agg act gga ag-3′ 5′-gga agt aag cca ctg cca ag-3′
b-actin 5′- tca ccg agc gcg gct-3′ 5′-taa tgt cac gca cga ttt ccc-3′
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pretreated with ODQ together or not with BAY 41-2272 for
48 h before PMA or IFN-g stimulation. In both treatments,
ODQ was given 1 h before treatments to guarantee its
binding and inactivation of sGC. After this, we performed the
same protocols described above, and analysed superoxide
release and phagocytosis.
Data analysis and statistical procedures
Results are expressed as mean  SEM of n experiments. Sta-
tistical analysis was carried out using a two-way ANOVA fol-
lowed by the Bonferroni post-test for multiple comparisons
(Erceg-Hurn and Mirosevich, 2008). Graphpad Prism version
5.0 (GraphPad, San Diego, CA, USA) was used to perform
statistical analysis; results were deemed significant if P < 0.05.
Drugs, chemicals reagents and
other materials
Human IFN-g was purchased from R&D Systems (Minneapo-
lis, MN), and PMA from Sigma (St. Louis, MO, USA). BAY
41-2272 was provided by Pharma Research Center, Bayer AG
(Wuppertal, Germany).
Results
BAY 41-2272 does not affect cell viability
Since a high rate of toxicity would not be an appropriate
feature for a potential treatment, we evaluated the effects of
BAY 41-2272 on cell viability. The MTT reduction assay
showed that neither 30 nor 120 min exposure of human PBM
or THP-1 cells to BAY 41-2272 (1.0–10.0 mM) caused any toxic
effect (two-way ANOVA, n = 6, P > 0.05; Table 2). The vehicle
used for BAY 41-2272 (0.7% DMSO) also does not affect cell
viability.
BAY 41-2272 increases IFN-g- and
PMA-induced superoxide production by
human PBM and THP-1 cells
As ROS is known to have an important function in cell-
mediated microbial death, we assessed whether BAY 41-2272
directly stimulated ROS production, as assayed by lucigenin-
chemiluminescence. We used IFN-g and PMA to stimulate
ROS production and enable comparison between these treat-
ments and BAY 41-2272 stimulation. BAY 41-2272 (1.0 and
3.0 mM) increased the amount of superoxide released by PBM
and THP-1 cells after direct stimulation for 2 h (two-way
ANOVA, n = 6, P < 0.05) and also after 48 h with the 3.0 mM
dose. BAY 41-2272 primed the PBM and THP-1 cells so that
both IFN-g and PMA were more potent at releasing superox-
ide after stimulation for 48 h (two-way ANOVA, n = 6, P < 0.05;
Figure 1A,B).
BAY 41-2272 augments the expression of
CYBB and NCF2 genes
The activation of the NADPH oxidase system involves the
phosphorylation of p47PHOX and assembly of its components
(El-Benna, 2005). In addition, regulation of the activity of the
NADPH oxidase system also involves gene expression
(Condino-Neto et al., 1998). Therefore, we assessed whether
BAY 41-2272 had an effect on CYBB, CYBA, NCF1 and NCF2
Table 2
Effect of BAY 41-2272 on the viability of PBM or THP-1 cells
Cells Treatment
MTT reduction (% control)
30 min 120 min
PBM 1.0 mM BAY 41-2272 95.32  5.41 104.30  2.10
3.0 mM BAY 41-2272 98.62  2.35 102.80  0.44
10.0 mM BAY 41-2272 98.01  3.34 99.12  3.00
3.0 mM BAY 41-2272 + 100 U·mL-1 IFN-g 72  1.45 44  2.65*
0.7% DMSO 98.75  2.87 96.07  3.05
30 nM PMA 94.03  3.32 92.13  2.72
300 nM PMA 92.10  0.38 68.45  2.62*
THP-1 1.0 mM BAY 41-2272 102.00  5.20 101.40  1.96
3.0 mM BAY 41-2272 98.05  0.65 106.85  2.62
10.0 mM BAY 41-2272 97.98  3.06 105.78  1.70
3.0 mM BAY 41-2272 + 100 U·mL-1 IFN-g 78  2.31 56  0.20*
0.7% DMSO 106.44  2.07 102.05  4.17
30 nM PMA 98.45  2.65 94.76  3.10
300 nM PMA 94.65  2.54 84.33  2.23*
Human PBM or THP-1 cell suspensions (2 ¥ 106 cells·mL-1) were incubated at 37°C for 30 min or 120 min with BAY 41-2272 (1.0–10.0 mM)
or PMA (30 or 300 nM). Each experiment was carried out in quintuplicate (n = 5).
The results are expressed as MTT reduction (% control, mean  SEM).
*ANOVA, P < 0.05.
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gene expression. Treatment of PBM and THP-1 cells with BAY
41-2272 for 48 h caused a significant increase in CYBB and
NCF2 expression, but not in CYBA and NCF1, both at 1.0 and
3.0 mM (two-way ANOVA, n = 6, P < 0.05; Figure 2) compared
with basal gene expression.
BAY 41-2272 increases p67PHOX and gp91PHOX
protein expression
As we had demonstrated that BAY 41-2272 increased the
levels of expression of CYBB and NCF2, we evaluated the
protein expression of NADPH oxidase components. Our
Western blot results confirmed that BAY 41-2272 increased
the expression of p67PHOX but no changes in protein expres-
sion of p22PHOX and p47PHOX were observed (two-way ANOVA,
n = 4, P < 0.05; Figure 3A). Similarly, the flow cytometry of
gp91PHOX showed an increased expression of this protein in
groups treated with BAY 41-2272 (two-way ANOVA, n = 4, P <
0.05; Figure 3B). These results show that gene and protein
expression of these components was increased (Figure 2).
BAY 41-2272 increases spreading
and phagocytosis
The early defence response of mononuclear phagocytes
involves the ingestion of microorganisms and the generation
of activation signals by these cells. BAY 41-2272 (1.0 and
3.0 mM), treatment for 1 h or 48 h, increased the phagocyto-
sis of zymosan induced by PBM and THP-1 cells (two-way
ANOVA, n = 6, P < 0.05; Figure 4B,D). The same pattern of
response was observed for spreading (Figure 4A,C).
BAY 41-2272 increases the bactericidal
activity against E. coli
Phagocytosis and ROS generation by mononuclear phago-
cytes have been kinetically correlated with increased bacteri-
cidal activity (DeLeo et al., 1999). Treatment with BAY
41-2272 (1.0 or 3.0 mM) produced a significant increase in the
bactericidal activity of PBM and THP-1 cells against EPEC
(two-way ANOVA, n = 6, P < 0.05; Figure 5A,B). These results
showed even higher significance for opsonized bacteria.
BAY 41-2272 increases the release of TNF-a
and IL-12p70
Cytokine production is a major aspect of the immune
response and they are involved in both effector and regula-
tory mechanisms, including mononuclear phagocytes (Geiss-
mann et al., 2008). Culturing PBM and THP-1 cells with BAY
41-2272 (1.0 and 3.0 mM) for 48 h caused an increase in
TNF-a and IL-12p70 production (two-way ANOVA, n = 6, P <
0.05; Figure 6).
Figure 1
BAY 41-2272 primed THP-1 cells and PBM for a potent release of superoxide after IFN-g or PMA stimulation. BAY 41-2272 treatment (1.0 or
3.0 mM) for 2 and 48 h increases superoxide release in THP-1 (A) and PBM (B), as assessed by lucigenin-chemiluminescence assay, and was even
more effective with subsequent stimulation with PMA (30 nM) or IFN-g (100 U·mL-1) for 2 h. Results are expressed in RLU as a mean  SEM of
maximum production (n = 6 healthy volunteers, in triplicate for PBM, or n = 6 independent experiments, in triplicate, for THP-1). CONT: no
stimulus. *P < 0.05, compared with basal production; **P < 0.05, compared with basal and BAY 41-2272 2 h treatment, by two-way ANOVA
followed by Bonferroni test.
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BAY 41-2272 produces effects on PBM and
THP-1 cells through sGC pathway,
specifically inhibited by ODQ
To clarify the pathways involved in the effects of BAY
41-2272, we inhibited sGC with ODQ to evaluate the specific
interaction of the drug with this enzyme. We observed that
treatment with ODQ did not result in a significant reduction
of BAY 41-2272 effects on the parameters investigated, even
when cells were treated with the higher dose of the com-
pound (3 mM). With regard to the production of ROS (two-
way ANOVA, n = 6, P < 0.05; Figure 7), the groups treated with
BAY 41-2272 plus ODQ did not show a significant reduction
in ROS production in any of the concentrations used. Even
when we did the pretreatment for 48 h, in the absence or
presence of ODQ, BAY 41-2272 still showed considerable
effects on ROS production (two-way ANOVA, n = 6, P < 0.05;
Figure 7C,D). Similar results were found for phagocytosis
(two-way ANOVA, n = 6, P < 0.05; Figure 8), using the same
incubation protocol.
Discussion and conclusions
The present study clearly demonstrates that 2 or 48 h treat-
ment with BAY 41-2272 (1.0 or 3.0 mM) caused a marked
increase in the activation of PBM and THP-1 cells, as demon-
strated by induction of oxidative burst, increased phagocyto-
sis and microbicidal activity, enhancement of IL-12p70 and
TNF-a release, and also increased expression of CYBB and
NCF2 genes in these cells. These observations support the
hypothesis that BAY 41-2272 activates mononuclear phago-
cytes and has the potential to be used in the control of
infections in the immunocompromised host.
Figure 2
BAY 41-2272 increases CYBB (gp91PHOX) and NCF2 (p67PHOX), but not CYBA (p22PHOX) or NCF1 (p47PHOX), expression in THP-1 cells (A–B–C–D) and
PBM (E–F–G–H). THP-1 (A–B–C–D) and PBM (E–F–G–H) treated with BAY 41-2272 (1.0 or 3.0 mM) increases CYBB and NCF2 expression levels after
48 h, quantified by qRT-PCR normalized to b-actin. BAY 41-2272 was less effective than IFN-g (100 U·mL-1) treatment for the same time. Dashed
line represents expression of genes in untreated cells. Results are shown as mean  SEM of expression relative to untreated group (n = 6 healthy
volunteers, in triplicate for PBM, or n = 6 independent experiments, in triplicate for THP-1). *P < 0.05, compared with basal expression, by two-way
ANOVA followed by Bonferroni test.
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ROS have an important function in cell-mediated micro-
bial death and are an important indicator of monocytic cell
activation (Huang et al., 2008). We used IFN-g (a receptor-
mediated activator) and PMA (a direct PKC activator) to
stimulate ROS production as positive controls and, after treat-
ment with BAY 41-2272, to test its potential for priming cells.
We observed that BAY 41-2272 induced a marked increase in
superoxide production, which may be related to PKC stimu-
lation of the sGC–cGMP signalling pathway (Khare et al.,
1994; Aggelidou et al., 2002). PKC promotes ‘phagocyte
oxidase’ phosphorylation and activation of the NADPH
oxidase system (Ueyama et al., 2007). Moreover, activation of
PKC may explain the high response after just 2 h of treat-
ment, since an increase in gene expression after this short
time is not likely to occur for most genes, including the
NADPH oxidase-related genes and proteins (Newburger et al.,
1988).
As extensively described, activation of the NADPH
oxidase system involves phosphorylation and clustering of
proteins in membranes, but the maintenance of the response
depends on the expression of new NADPH oxidase compo-
nents (Quinn et al., 2006). Our results show that BAY 41-2272
markedly increases in the expression of CYBB and NCF2.
Moreover, the protein expression of the NADPH oxidase com-
ponents (p67PHOX and gp91PHOX) was also increased, confirm-
ing the data obtained by qRT-PCR. These results are similar to
those found by Newburger et al. (1991), who showed an
increase in the expression of these genes by up to 12 times
after 24 h incubation of PBM with IFN-g and also, similarly,
Condino-Neto et al. (1998) found that IFN-g increased the
expression of CYBB in THP-1 cells. These results suggest that
BAY 41-2272 stimulates not only signalling pathways but also
important transcriptional factors related to the expression of
CYBB and NCF2 genes, such as STAB1, CDP (Hawkins et al.,
2001) and Pbx1, constitutively expressed in THP-1 (Skalnik
and Neufeld, 1992; Eklund et al., 2000); HAF-1 (Newburger
et al., 1994; Suzuki et al., 1998); and PU.1/IRF1/ICSBP/CBP
(Eklund and Kakar, 1999). Recently, Luengo-Blanco et al.
(2008) reported that binding of NF-kB transcription factor to
CYBB is important for NAPDH oxidase function. Since there
was a marked increased production of TNF-a, which is depen-
dent on NF-kB activation (Ci et al., 2008), we suggest that BAY
41-2272 may activate the signalling pathways involved in
NF-kB activation.
In addition to ROS release, phagocytosis is an essential
function that should be analysed in phagocytes. Signal path-
ways activated by BAY 41-2272 are involved in cGMP genera-
tion and are linked to morphological changes required for
migration, phagocytosis and spreading (Borán and García,
2007). We showed that BAY 41-2272 increased phagocytosis
Figure 3
BAY 41-2272 increases p67PHOX and gp91PHOX protein expression, but not p22PHOX and p47PHOX. PBM (1 ¥ 107 cells·mL-1 for Western blot and 1 ¥
106 cells·mL-1 for flow cytometry) treated with BAY 41-2272 (1.0 or 3.0 mM) increased p67PHOX (A) and gp91PHOX (B) expression after 48 h, as
quantified by Western blot (normalized to b-actin) and flow cytometry, respectively. Cells were also treated with IFN-g (100 U·mL-1) and PMA
(30 nM for flow cytometry). Dashed line represents basal expression normalized to b-actin expression. For Western blot, results are shown as a
representative blot figure and as total pixel intensity of the blots. For flow cytometry, results are shown as mean  SEM of percentage of cells
expressing gp91PHOX or mean  SEM of MFI (n = 4 healthy volunteers, in triplicate). *P < 0.05, compared to basal protein expression, by two-way
ANOVA followed by Bonferroni test.
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Figure 4
BAY 41-2272 increases spreading and phagocytosis of THP-1 cells and PBM. THP-1 (A, B) and PBM (C, D) (1 ¥ 106 cells·mL-1) pretreated with BAY
41-2272 for 48 h increased the spreading and phagocytic activity against zymosan. BAY 41-2272 (1.0 or 3.0 mM) treatment was even more
effective when PMA (30 nM) and IFN-g (100 U·mL-1) were added for 2 h after pretreatment. Number of spreading or phagocytosing cells is
expressed as a percentage  SEM of 200 total cells counted (n = 6 healthy volunteers, in triplicate for PBM, n = 6 independent experiments for
THP-1).*P < 0.05, compared with basal (spreading or phagocytosis); **P < 0.05, compared to cells not pretreated, by two-way ANOVA followed
by Bonferroni test.
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and this can be explained by PKG activation, as this was
recently shown by Bóran et al. (2008) to promote a rapid
release and expansion of filaments in microglia cells and
increase in the phagocytosis function after treatment with
ANP (another sGC stimulator) and dibutyryl-cGMP (perme-
able analogue of cGMP).
The phagocytosis activity and oxidative burst by mono-
nuclear phagocytes have been kinetically correlated with
increased bactericidal activity. It is recognized that ROS are
highly toxic to bacteria such as E. coli (Nauseef, 2007),
and this increase is probably related to the amount of oxida-
tive burst and phagocytosis. However, other important
parameters such as acidification of phagosome pH and release
of lysosomal enzymes and granules (Ismail et al., 2002) have
not yet been evaluated. Therefore, we cannot exclude a pos-
sible involvement of other factors such as the expression of
surface molecules like Fc and complement receptors, making
the phagocytosis more efficient and generating other signals
that increase the phagocyte killing (Jongstra-Bilen et al.,
2003; Luo et al., 2006; Rhein et al., 2008).
All these effects may be related to cytokine production
involved with cellular activation and enhancement of the
immune response. According to our expectations, treatment
with BAY 41-2272 generated an increase in IL-12p70 release,
since activated monocytes and macrophages produced high
levels of these cytokines (Murray et al., 2006). BAY 41-2272
also promoted an increased production of TNF-a, strongly
suggesting that this drug can activate MAPKs or NF-kB sig-
nalling pathways (Igbal and Zaidi, 2008). In addition, TNF-a
production is thought to act like an autocrine, signalling cell
activation by acting on the TNF-a receptor in monocyte cells
(Deering and Orange, 2006).
Since we observed a wide spectrum of functions acti-
vated in treated phagocytes, we wondered whether all
these effects of BAY 41-2272 resulted from an effect involv-
ing the sGC cyclase pathway. We observed that treatment
with ODQ, a sGC specific inhibitor, did not result in a sig-
nificant reduction of BAY 41-2272-induced superoxide pro-
duction and phagocytosis. These results show that the
effects of the compound are not related only to the sGC
Figure 5
BAY 41-2272 increases microbicidal activity of THP-1 cells and PBM. Pretreatment of THP-1 (A) and PBM (B) (1 ¥ 106 cells·mL-1) with BAY 41-2272
(1.0 or 3.0 mM) for 48 h increased their microbicidal activity against EPEC, assessed by CFU counting from recovering internalized bacteria after
co-culture. As positive control, cells were treated with IFN-g (100 U·mL-1) for 48 h. Microbicidal activity is expressed as percentage  SEM of
maximum killing (minimum bacterial survival) (n = 6 healthy volunteers, in triplicate for PBM, n = 6 independent experiments, in triplicate for
THP-1). *P < 0.05, compared with basal bacterial activity; **P < 0.05, compared with cells in same treatment condition, cultured with bacteria
opsonized or not, by two-way ANOVA followed by Bonferroni test.
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cyclase pathway, presenting activity on other signalling
pathways.
Oliveira-Junior et al. (2007) showed that BAY 41-2272 is
able to generate an increased production of cAMP, another
important second messenger. Based on this, we suggest that
other important pathways are activated by this compound.
This increased production of cAMP could be due to a direct
effect of the drug on the enzyme adenylate cyclase or an
indirect effect through the production of cGMP. In addition
to this hypothesis, Derbyshire et al. (2009) showed that the
catalytic domains of GCs contain a catalytic and allosteric site
capable of binding to both GTP and ATP nucleotides. This
same group showed that the action of YC-1, a BAY 41-2272
analogue, leads to the production of cGMP and cAMP. This
another alternative action of the drug, beyond the pathway
involving sGC–cGMP–PKG.
Based on our results using ODQ and the results found
by Koglin et al. (2002), showing BAY 41-2272 binding
sites at two isoforms of sGC, we started to perform an
in silico analysis of proteins with potential binding sites
for BAY 41-2272. In our initial analysis, we found four
proteins with potential binding sites for this compound
and functions related to differentiation/activation of
myelomonocytic cells (data not shown). These results open
a new way of thinking for BAY 41-2272 analysis and new
pathways involved in the activation of human myelomono-
cytic cells.
In summary, our present study consistently demonstrated
that BAY 41-2272 activates human mononuclear phagocytes
and has a great potential to control infections. However, the
cardiovascular effects of BAY 41-2272 limit its clinical appli-
cation, and this should be addressed in future in in vivo
experimental and pre-clinical studies. Moreover, additional
studies to clarify the signalling pathways involved in phago-
cyte activation will help to elucidate and modulate the effects
of BAY 41-2272 both in the cardiovascular and immune
Figure 6
BAY 41-2272 increases the production of IL-12p70 and TNF-a by THP-1 cells and PBM. THP-1 (A,B) and PBM (C,D) cells (1 ¥ 106 cells·mL-1)
pretreated with BAY 41-2272 (1.0 or 3.0 mM) for 48 h increased TNF-a and IL-12p70 production. As positive control, cells were treated with IFN-g
(100 U·mL-1) for 48 h. Results are expressed as mean  SEM (n = 6 healthy volunteers, in triplicate for PBM, n = 6 independent experiments, in
triplicate for THP-1). *P < 0.05, compared with basal cytokine production, by one-way ANOVA followed by Bonferroni post-test.
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Figure 7
BAY 41-2272 affects superoxide production in a manner not exclusively dependent on the sGC pathway. BAY 41-2272 treatment (1.0 or 3.0 mM)
for 2 h (A,B) and 48 h (C,D) increased superoxide release in PBM and THP-1 cells (1 ¥ 106 cells·mL-1), as assessed by lucigenin-chemiluminescence
assay, even when sGC was specifically inhibited with ODQ (100 mM). We also treated cells with PMA (30 nM) or IFN-g (100 U·mL-1) for 2 h, as
controls. Dashed line represents expression of genes in untreated cells. Results are expressed in RLU as a mean  SEM of maximum production
(n = 4 healthy volunteers, in triplicate for PBM, or n = 4 independent experiments, in triplicate, for THP-1). *P < 0.05, compared with basal
production by two-way ANOVA followed by Bonferroni test.
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Figure 8
BAY 41-2272 affects phagocytosis in a manner not exclusively dependent on the sGC pathway. BAY 41-2272 treatment (1.0 or 3.0 mM) for 2 h
(A,B) and 48 h (C,D) increases phagocytic activity of PBM and THP-1 cells (1 ¥ 106 cells·mL-1) against zymosan, even when sGC was specifically
inhibited with ODQ (100 mM). We also treated cells with PMA (30 nM) or IFN-g (100 U·mL-1) for 2 h, as controls. Dashed line represents
expression of genes in untreated cells. Number of phagocytosing cells is expressed as a percentage SEM of 200 total cells counted (n = 4 healthy
volunteers, in triplicate for PBM, n = 4 independent experiments for THP-1). *P < 0.05, compared with basal spreading or phagocytosis; **P < 0.05,
compared to cells not pretreated cells, by two-way ANOVA followed by Bonferroni test.
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systems. In addition, the effects of BAY 41-2272 in other
immune cells, such as lymphocytes, are also needed to eluci-
date how this drug works and its potential applications for
the immunocompromised host.
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